These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30262247)

  • 1. Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A.
    Burkhardt M; Reiter K; Nguyen V; Suzuki M; Herrera R; Duffy PE; Shimp R; MacDonald NJ; Olano LR; Narum DL
    Vaccine; 2019 Sep; 37(38):5762-5769. PubMed ID: 30262247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host cell protein quantification of an optimized purification method by mass spectrometry.
    Reiter K; Suzuki M; Olano LR; Narum DL
    J Pharm Biomed Anal; 2019 Sep; 174():650-654. PubMed ID: 31279895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
    Pier GB
    Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
    [No Abstract]   [Full Text] [Related]  

  • 5. [Study of protective properties of recombinant atoxic form of exotoxin A and recombinant outer membrane protein F of Pseudomonas aeruginosa].
    Mikhaĭlova NA; Vertiev IuV; Kaloshin AA; Isakov MA
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):39-44. PubMed ID: 20464999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
    Weldon JE; Pastan I
    FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.
    Tanomand A; Farajnia S; Najar Peerayeh S; Majidi J
    Iran Biomed J; 2013; 17(1):1-7. PubMed ID: 23279828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
    Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
    Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
    Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE
    Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Production and properties evaluation of monoclonal antibodies against Pseudomonas aeruginosa exotoxin A].
    Soldatenkova AV; Iakovleva IV; Gavrilova NV; Mikhaĭlova NA; Sviridova VV
    Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):30-5. PubMed ID: 24738291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A.
    Wade TK; Saksena R; Shiloach J; Kovác P; Wade WF
    FEMS Immunol Med Microbiol; 2006 Nov; 48(2):237-51. PubMed ID: 17010106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli.
    Song S; Xue J; Fan K; Kou G; Zhou Q; Wang H; Guo Y
    Protein Expr Purif; 2005 Nov; 44(1):52-7. PubMed ID: 15922623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico integrative analysis predicts relevant properties of exotoxin-derived peptides for the design of vaccines against Pseudomonas aeruginosa.
    Terra ACG; Salvador EA
    Infect Genet Evol; 2020 Nov; 85():104424. PubMed ID: 32561294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
    Ho MM; Bolgiano B; Martino A; Kairo SK; Corbel MJ
    Hum Vaccin; 2006; 2(3):89-98. PubMed ID: 17012902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunobiological properties of recombinant atoxic forms of the Pseudomonas aeruginosa exotoxin A].
    Isakov MA; Soldatenkova AS; Kaloshin AA; Mikhaĭlova NA
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):37-42. PubMed ID: 21598613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.
    Joshi BH; Puri RK
    Protein Expr Purif; 2005 Feb; 39(2):189-98. PubMed ID: 15642470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model.
    Safari Zanjani L; Shapouri R; Dezfulian M; Mahdavi M; Shafiee Ardestani M
    World J Microbiol Biotechnol; 2019 Jun; 35(6):94. PubMed ID: 31187291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects.
    Liao CW; Chen CA; Lee CN; Su YN; Chang MC; Syu MH; Hsieh CY; Cheng WF
    Cancer Res; 2005 Oct; 65(19):9089-98. PubMed ID: 16204084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.
    Cuccui J; Thomas RM; Moule MG; D'Elia RV; Laws TR; Mills DC; Williamson D; Atkins TP; Prior JL; Wren BW
    Open Biol; 2013 May; 3(5):130002. PubMed ID: 23697804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.